Contents
01 November 2017
Vol 9, Issue 414
Vol 9, Issue 414
Research Articles
- A completely biological “off-the-shelf” arteriovenous graft that recellularizes in baboons
A decellularized tissue tube grown from human skin cells and fibrin becomes repopulated by recipient cells when tested in baboons as a vascular graft for hemodialysis access.
- A precision therapy against cancers driven by KIT/PDGFRA mutations
BLU-285 is a selective and potent mutant KIT and PDGFRA inhibitor active in both preclinical and clinical settings.
- A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates
A population of hematopoietic stem cells with superior engraftment and repopulating abilities has been identified in nonhuman primates.
- Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors
PGBD5 DNA transposase confers therapeutically actionable dependency in solid tumors.
- The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study
A first-in-human study of rozanolixizumab (UCB7665), an antihuman FcRn monoclonal antibody for IgG autoantibody-mediated diseases, is reported.
Editors' Choice
- Listening with your heart
A subtle change in heart rate variability might indicate ongoing cognitive processing.
- Blood helps lungs miss the TRALI
RBCs limit lung injury by sequestering circulating mitochondrial DNA.
- Searching for the ovarian cancer cell of origin
Genomic analyses of ovarian cancer evolution suggest an origin in the fallopian tube.
- Sugar, drugs, and gut bugs
A high-fat diet in rodents causes changes in gut microbiota and glucose sensing that may be mitigated by treatment with metformin.
About The Cover
ONLINE COVER Building Blood Vessels. This image shows a cross-section of a tissue-engineered vascular graft. Syedain et al. constructed these tubes from fibrin protein and human skin cells. During culture in a bioreactor, skin cells converted the fibrin into collagen. After removing the cells from the tubes, these grafts were implanted into baboons as arteriovenous grafts. Over the course of 6 months, cells repopulated the grafts and the grafts maintained patency. These grafts offer a biological alternative to synthetic vascular grafts used for hemodialysis access in patients. [CREDIT: COLE FEAGLER/UNIVERSITY OF MINNESOTA]